Aethlon Medical announces merger with North Immunology and reports Q2 2027 results

Aethlon Medical disclosed its fiscal second‑quarter 2027 financials and said it entered a merger agreement with North Immunology on September 17, 2026. The deal will create a combined company that will operate under the North Immunology name and includes a contingent value right for Aethlon shareholders. The company also reported a workforce reduction and continued enrollment in its Phase 1 oncology trial in Australia.

The merger could reshape Aethlon's business focus and may lead to further cost reductions, affecting the company's cash position and future earnings potential. Holders of Aethlon common stock will receive contingent value rights that could provide upside if the legacy Hemopurifier assets are monetized.

  • 1Aethlon entered a Plan of Merger and Reorganization with North Immunology on September 17, 2026.
  • 2The combined entity is expected to be called North Immunology, Inc. after the merger.
  • 3Aethlon implemented workforce reductions near the end of the second fiscal quarter.
  • 4Aethlon’s Phase 1 oncology study in Australia treated eight patients across three dosing cohorts, with a second participant treated in the final cohort during the quarter.
  • 5Cash and cash equivalents were about $6.5 million as of September 30, 2026.
  • 6Consolidated operating expenses rose 77.2% to roughly $2.7 million for the quarter, compared with about $1.5 million in the prior‑year quarter.

Sources